Publications

Qureshi R, Kindo M, Arora H, Boulberdaa M, Steenman M, Nebigil CG (2017). Prokineticin receptor-1-dependent paracrine and autocrine pathways control cardiac tcf21+ fibroblast progenitor cell transformation into adipocytes and vascular cells. Sci Rep 7:12804.

Nebigil CG (2017). Prokineticin is a new linker between obesity and cardiovascular diseases. Frontiers in Cardiovas Med 4:20.

Nebigil CG (2016). Updates on endothelial functions of pro-angiogenic prokineticin. Hypertension 68:1091-1097.

Arora H, Boulberdaa M, Qureshi R, Bitirim V, Gasser A, Dolle P, Nebigil CG (2016). Prokineticin receptor-1 is essential for epicardial- mesenchymal transition to regulate cardiac development and function. Sci Rep 6:25541.

Arora H, Boulberdaa M, Qureshi R, Bitirim V, Dolle P, Nebigil CG (2016). Prokineticin receptor-1 is essential for mesenchymal- epithelial transition to regulate renal development and function. FASEB J 30:2733-40.

Nebigil CG, Tounsi N, Fuhrmann G, Désaubry L (2016). Quo Vadis, Cardio-Oncology? Adv Oncol Res Treat 1:102.

Nebigil CG (2016). Obesity peptides and Prokineticin. In: Obesity (Jan Oxholm Gordeladze, eds.) Transworld Research Network - ISBN 978-953-51-4998-9.

Qureshi R, Yildirim O, Gasser A, Basmadjian C, Zhao Q, Wilmet JP, Désaubry L, Nebigil CG (2015). Fl3 a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity. PLoS One 10(11):e0141826.

Von Hunolstein JJ, Nebigil CG (2015). Can Prokineticin Prevent Obesity and Insulin Resistance? Curr Opin Endocrinol Diabetes Obes 22:367-73.

Gasser A, Brogi S, Urayama K, Nishi T, Kurose H, Tafi A, Ribeiro N, Désaubry L, Nebigil CG (2015).  Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One 10:e0121027.

Brogi S, Gasser A, Désaubry L, Nebigil CG (2014). Discovery of GPCR ligands for probing signal transduction pathways. Front Pharmacol 5:255.

Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG (2014). Cancer wars: natural products strike back. Front Chem 2:20.

Basmadjian C, Zhao Q, de Gramont A, Serova M, Faivre S, Raymond E, Vagner S, Robert C, Nebigil CG, Désaubry L (2014). Synthesis and pharmacology of flavaglines, in Bioactive natural products: chemistry & biology, edited by Dr. Goutam Brahmachari, Wiley-VCH.

Nguyen TL, Gasser A, Nebigil CG (2013). Role of Prokineticin Receptor−1 in Epicardial Progenitor Cells. J Dev Biol 1: 20−31.

Szatkowski C, Valet P, Boulberdaa M, Metzger D, Chambon P, Nebigil CG (2013). Prokineticin receptor-1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity. Plos One 8:e81175.

Dormishian M, Turkeri, Boulberda M, Henrion D, Nebigil CG (2013).  Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions. J Am Heart Assoc 2:e000411

Thuaud F, Ribeiro N, Nebigil CG, Désaubry L (2013). Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chem Biol 20:316–331.

Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, Hild A, Hirsch EC, Michel PP, Nebigil CG, Désaubry L (2012). Flavaglines as potent anticancer and cytoprotective agents. J Med Chem 55:10064-73.

Ribeiro N, Thuaud F, Nebigil CG, Désaubry L (2012). Recent advances in the biology and chemistry of the flavaglines. Bioorg Med Chem 20:1857-64.

Nebigil CG (2012).  Role of prokineticin in epicardial progenitor cell differentiation to regenerate heart. In: Current Basic and Pathological Approaches to the Function of Muscle Cells and Tissues - From Molecules to Humans (Haruo Sug, ed) InTechopen-ISBN 978-953-51-0679-1.

Boulberdaa M, Urayama K, Nebigil CG (2011). Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney functions. Cardiovas Res 92:191-8.

Bernard Y, Ribeiro N, Thuaud F, Türkeri G, Dirr R, Boulberdaa M, Nebigil CG, Désaubry L (2011). Flavaglins alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS One 6:e25302.

Boulberdaa M, Turkeri G, Urayama K, Dormishian M, Swzatkowski C, Messaddeq N, Dolle P and Nebigil CG (2011). Loss of PKR1 in mice induces heart and kidney disorders. Arter Thromb Vas Biol 31:842-850.

Guilini C, Urayama K, Turkeri G, Dedeoglu DB, Kurose H, Messaddeq N, Nebigil CG (2010). Divergent role of prokineticin receptors in endothelial cells: Angiogenesis and fenestration. Am J Physiol Heart Circ 298: H844-52.

Nebigil CG (2010). Prokineticin receptors in cardiovascular function. In: Shaping the Heart in Development and Disease (Alexander T. Mikhailov and Mario Torrado, eds.) Transworld Research Network - ISBN:978-81-7895-444-8.

Urayama K, Dedeoglu DB, Messaddeq N, Hu K, Ert G, Nebigil CG (2009). Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage. Cardiovasc Res 81: 28-37.

Urayama K, Guilini C, Turkeri G, Takir S, Messaddeq N, Nebigil CG (2008). Prokineticin receptor-1 induces neovascularization and epicardial derived progenitor cell differentiation. Arter Thromb Vas Biol 28:841-9.

Urayama K, Guilini C, Messaddeq N, Hu K, Steenman M, Kurose H, Ert G, Nebigil CG (2007). The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis. FASEB J 21:2980-93.